Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Detecting respiratory viral RNA using expanded genetic alphabets and self-avoiding DNA

Lyudmyla G. Glushakovaa, Nidhi Sharma b, Shuichi Hoshikab, Andrea C. Bradleymb, Kevin M. Bradleymb, Zunyi Yangb, Steven A. Bennera, b, *

a Firebird Biomolecular Sciences, Alachua, FL 32615, USA
b Foundation for Applied Molecular Evolution (FfAME), Alachua, FL 32615, USA

A R T I C L E   I N F O

Article history:
Received 14 June 2015
Received in revised form 7 August 2015
Accepted 13 August 2015
Available online 21 August 2015

Keywords:
Reverse transcription PCR
Luminex direct hybridization assay
Self-avoiding molecular recognition system (SAMRS)
Artificially expanded genetic information system (AEGIS)
Respiratory viruses

A B S T R A C T

Nucleic acid (NA)-targeted tests detect and quantify viral DNA and RNA (collectively xNA) to support epidemiological surveillance and, in individual patients, to guide therapy. They commonly use polymerase chain reaction (PCR) and reverse transcription PCR. Although these all have rapid turnaround, they are expensive to run. Multiplexing would allow their cost to be spread over multiple targets, but often only with lower sensitivity and accuracy, noise, false positives, and false negatives; these arise by interactions between the multiple nucleic acid primers and probes in a multiplexed kit. Here we offer a multiplexed assay for a panel of respiratory viruses that mitigates these problems by combining several nucleic acid analogs from the emerging field of synthetic biology: (i) self-avoiding molecular recognition systems (SAMRSs), which facilitate multiplexing, and (ii) artificially expanded genetic information systems (AEGISs), which enable low-noise PCR. These are supplemented by “transliteration” technology, which converts standard nucleotides in a target to AEGIS nucleotides in a product, improving hybridization. The combination supports a multiplexed Luminex-based respiratory panel that potentially differentiates influenza viruses A and B, respiratory syncytial virus, severe acute respiratory syndrome coronavirus (SARS), and Middle East respiratory syndrome coronavirus (MERS) coronavirus, detecting as few as 10 MERS virions in a 20-μl sample.

© 2015 Elsevier Inc. All rights reserved.

It has been a quarter-century since it was first shown that by rearranging hydrogen bond donor and acceptor groups within the Watson–Crick nucleobase pairing geometry, eight additional nucleotides forming four additional nucleobase pairs could be added to the DNA alphabet (Fig. 1) [1]. Almost immediately, these artificially expanded genetic information systems (AEGISs) were adapted for use in diagnostics assays. These exploited the ability of AEGIS DNA to pair with AEGIS DNA without off-target hybridization to the standard nucleic acids, which are always abundant in real biological samples. Best known of these are the branched DNA assays that used two matched AEGIS components, IsoC and IsoG, in a signaling dendrimer to measure viral loads in patients infected with HIV, hepatitis B, or hepatitis C [2,3]. These products received Food and Drug Administration (FDA) approval in 2004 and were used to personalize the care of some 400,000 patients per year before the product was retired in 2014. These viral load assays exploited AEGIS components only for their ability to form orthogonal nucleobase pairs in a hybridization format; they did not take advantage of the ability of AEGIS DNA (like standard DNA) to be amplified using the polymerase chain reaction (PCR) [4]. This staged introduction of AEGIS nucleotides into diagnostics is understandable. Hybridization is simple. In contrast, PCR amplification requires that polymerases copy unnatural AEGIS pairs again and again with high efficiency and high fidelity.
The AEGIS:AEGIS isoC:isoG pair was introduced a decade ago into a diagnostics kit that exploited polymerases to incorporate, from triphosphates, the isoC:isoG pair into duplex products [5]. Unfortunately, isoG exists (~10% of the total) in a minor tautomeric form that is complementary to natural thymidine, not to IsoC. This required those tools to add isoGTP opposite isoC in a template and not the reverse; if isoG were in the template, T would be misincorporated opposite isoG a substantial fraction of the time. Nevertheless, even with this constraint, assays were commercialized that combined the isoGTP:isoCTP pair with polymerases to detect nucleic acids from a panel of respiratory disease agents [6].

During the past 10 years, synthetic biology has advanced to a second generation of AEGIS nucleotides that mitigates these problems [7]. To this has been added a new class of DNA known as self-avoiding molecular recognition systems (SAMRSs). SAMRS nucleotides cannot interact with each other. Thus, SAMRS oligonucleotides added to a multiplex cannot create primer–dimer artifacts in multiplexed NA-targeted assays. AEGISs and SAMRSs can be combined to give cleaner and more robust responses in diagnostics assays.

As a third advance, procedures were developed that, during copying, do “transliteration,” replacing standard nucleotide “letters” to give AEGIS nucleotide “letters” without the loss of information [8]. Transliteration, in principle, confers advantages that AEGIS provides for capture (including uniform and highly efficient capture on Luminex beads) on DNA/RNA that originated as standard DNA or RNA. All AEGIS pairs are joined by three hydrogen bonds, allowing AEGIS pairing to avoid the problems seen when combining a “weak” A:T pair with a “strong” G:C pair. Furthermore, after they are transliterated, amplicons cannot be “distracted” by standard oligonucleotides that are invariably present in complex biological assay mixtures. A schematic diagram of multiplexed Luminex xMAP assays panel based on reverse transcription PCR (RT–PCR) amplification with transliteration is shown in Fig. 2.

We recently reported an AEGIS–SAMRS–transliteration assay that detected 22 arboviruses from mosquitoes [9]. Based on this
success, we decided to revisit respiratory viruses as the targets for assays to learn if they too could be improved using the AEGIS－SAMRS－transliteration combination [6]. Here we report the development of a small (6-plex) Luminex-based system that detects five of the most important and dangerous respiratory disease candidates: influenzas A and B (InfA and InfB, respectively), respiratory syncytial virus (RSV), and the coronaviruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). In addition to targeting “simulants” of these respiratory diseases (small in vitro produced RNAs), the kit was tested on full-length MERS, which was targeted at two of its genomic sites.

**Materials and methods**

**Viruses targeted in this study**

The viruses used in this study are shown in Table 1. Their RNA was obtained as simulants by transcription from the appropriate DNA templates using T7 RNA polymerases.

**Design of oligonucleotide primers and probes**

All amplifiers, primers, and probes for this study (except those targeting the U6 gene in MERS virus that were from Ref. [10]) (Tables 1 and 2) were designed with the help of StrainTargeter, an in-house software package [9]. StrainTargeter analyzes multiple sequence alignments (MSAs) of virus families built from public databases (GenBank, http://www.ncbi.nlm.nih.gov/genbank; ViPR, http://www.viprbrc.org; and FluDB, http://www.fludb.org), finding regions within those viral genomes that have a level of sequence divergence that allows viral targets to be distinguished, but not so much to prevent detecting viruses that are divergently evolving. A BLAST search then follows to ensure that primer and probe sequences designed by StrainTargeter are not closely similar to sequences in both the NCBI RNA virus database and the NCBI human genome database.

Single-stranded DNA (ssDNA) oligonucleotides to encode the viral RNA simulants, as well as all standard capture probes for the Luminex xMAP direct hybridization assays (DHAs) (Table 2; see also Table A1 in online supplementary material), were purchased from Integrated DNA Technologies (IDT, Coralville, IA, USA). All probes were 5'-amino–C12-modified (5AmMC12). Primers and capture probes containing artificial SAMRS and AEGIS nucleotides (Table 3) were synthesized on ABI 394 and ABI 3900 synthesizers from AEGIS and SAMRS phosphoramidites (Firebird Biomolecular Sciences); AEGIS and SAMRS oligonucleotides are also available from Firebird Biomolecular Sciences directly (http://www.firebirdbio.com). Primers and capture probes were designed by StrainTargeter to complement the majority of the sequences in the MSA created for each virus targeted. For the InfA and InfB, RSV, and SARS simulants RNA synthesis, ssDNA oligonucleotide templates (Table 2) were created from the consensus sequence of the designed amplicon to represent a single strain.

**In vitro production of viral RNA simulants via transcription by T7 RNA polymerase**

RNA simulants corresponding to the StrainTargeter amplicon of each viral strain (Table 1) were produced by the in vitro transcription using T7 RNA polymerase and the encoding DNA molecules. These were obtained in ssDNA form from IDT and PCR amplified. Each contained a T7 promoter universal sequence (5'-TAATACGACTCACTATAGGG-3') at its 5' end. The templates for the transcription reactions were PCR amplifications. PCR was done in 1 x JumpStart reaction buffer (10 mM Tris–HCl [pH 8.3], 50 mM KCl, 1.5 mM MgCl2, and 0.001% [w/v] gelatin; total volume 100 µl) (Sigma–Aldrich, St. Louis, MO, USA); other components of the reaction mixture were as follows: 2.5 ng/µl DNA oligo; dNTPs (Life Technologies, Carlsbad, CA, USA), 0.4 µM each; forward T7 primer and reverse target-specific primer; JumpStart Taq DNA polymerase (2 U; Sigma); and nuclease-free ddH2O (added to create a final volume of 100 µl). After the initial denaturation at 95 °C for 2 min, 35 heat cycles were performed (94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min). A final extension cycle was run at 72 °C for 5 min. Each PCR product was then ethanol precipitated and dissolved in nuclease-free ddH2O (10 µl). PCR product served as the T7 DNA template in the transcription reaction.

To make simulants, a T7 RNA polymerase-dependent transcription reaction mixture (20 µl) was set up in a 1 x transcription buffer (40 mM Tris–HCl [pH 7.8], 20 mM NaCl, 18 mM MgCl2, 2 mM spermidine HCl, and 10 mM dithiothreitol [DTT]; Life Technologies) that also contained ATP, CTP, GTP, and UTP (2 µl of 75-mM stock solutions; New England Biolabs [NEB], Ipswich, MA, USA), DNA template (2.5–5 pmol, purified and concentrated PCR product), and T7 RNA polymerase (2 µl of 200 U/µl to give 20 U/µl final concentration). Mixtures were incubated at 37 °C for 8–12 h. To remove DNA template, Turbo DNase was added (2 U per reaction mixture; Life Technologies), and mixtures were further incubated (37 °C, 15–20 min). RNA products were isolated by phenol–chloroform extraction and dissolved in nuclease-free water (20 µl). RNAs were resolved by 3% TBE gel electrophoresis and quantitated by ultraviolet (UV) absorbance at 260 nm. The purity of RNAs was evaluated from their A260/A280 ratio. For pure RNA, a ratio of 1.8–2.1 is expected. The absence of template DNA in the RNA samples was confirmed by conventional PCR with Platinum Taq DNA polymerase (Life Technologies) and the ethidium bromide gel. Samples were aliquoted and kept at −80 °C.

Monoplexed PCRs were executed with each target RNA simulant separately to assess the efficacy of the primers in PCR cycling as well as to determine the maximum sensitivity of the assay. Reactions were then optimized under multiplexed conditions to

---

**Table 1**

| Order/Family/Subfamily/Genus | Viruses and abbreviations |
|-----------------------------|--------------------------|
| Nidovirales/Coronaviridae/Coronavirinae/Betacoronavirus | Middle East respiratory syndrome coronavirus, MERS–CoV or EMC/2012 (HCoV–EMC/2012) (lineage C) |
| Group IV, positive, ssRNA | Severe acute respiratory syndrome coronavirus, SARS–CoV (lineage B) |
| Mononegavirales/Paramyxoviridae/Pneumovirinae/Pneumovirus | Human respiratory syncytial virus, RSV |
| Group V, negative ssRNA | Influenza A virus, InfA |
| Orthomyxoviridae/Influenza virus A | Influenza B virus, InfB |
| Group V, negative ssRNA | |
Table 2

| Amplimers in this study | Middle East respiratory syndrome (MERS) 1 (145 bp): |
|-------------------------|---------------------------------------------------|
|                         | CATGCTATTGCTTTAACGCTGAGGGTGATGCATCTTGGTCTTCTACTATGATCTTCTCTCTTCACCCCGTCGAGTGTGACGAGGAGTGTTCTGAAGTAGAGGCTTCAGATTTAGAAGAAGGTGAATCAGAGTGCATTTCTGAGAC |
|                         | MERS 2 (195 bp):                                   |
|                         | GATGTTGCTAACCCTAGCACTCCAGCCTACACTTTTACAACAGTGAAACCTGGCGCAGCATTTAGTGTGTTAGCATGCTATAATGGTCGTCCGACTGGTACATTCACTGTTGTAATGCGCCCTAACTACACAATTAAGGGTTCCTTTCTGTGTGGTTCTTGTGGTAGTGTTGGTTACACCAAGGAGGGTAGTGTG |
|                         | MERS 4 (136 bp):                                   |
|                         | GTCAAGACCTTGGCGTAGTATCCAAGGTTGTCAAGGTTCCTATTGACTTAACAATGATTGAGTTTATGTTATGGTGTAAGGATGGACAGGTTCAAACCTTCTACCCTCGACTCCAGGCTTCTGCAGATTGGAAACC |
|                         | MERS 6 (159 bp):                                   |
|                         | CTGGCATTGTAGCAGCTGTTTCAGCTATGATGTGGATTTCCTACTTTGTGCAGAGTATCCGGCTGTTTATGAGAACTGGATCATGGTGGTCATTCAATCCTGAGACTAATTGCCTTTTGAACGTTCCATTTGGTGGTACAACTGTCGTACGTCCACTC |
|                         | Respiratory syncytial virus (RSV) (126 bp):        |
|                         | GAGGAGGTTGTTCTCAAGAACGGTGAACTCGAAGCACTCGAGACGCCCGTTGATAGCTTCACAAATGGAGCTATCGTTGGCACACCAGTCTGTGTAAATGGCCTCATGCTCTTAGAGA |
|                         | Influenza A (InfA) (113 bp):                       |
|                         | CATGGAGTGGCTAAAGACAAGACCAATCCTGTCACCTCTGACTAAGGGGATTTTAGGATTTGTGTTCACGCTCACCGTGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTGInfluenza B (InfB) (120 bp): |
|                         | L.G. Glushakova et al. / Analytical Biochemistry 489 (2015) 62–72 |

Note. 5'-3': bp: length of oligonucleotide amplimer in base pairs.

Inactivated MERS virus (Jordanian isolate, GenBank accession no. KC164505.2) [10] was obtained from Lisa Hensley and Reed Johnson of the National Institute of Allergy and Infectious Diseases (Fort Detrick, Frederick, MD, USA) in the TRizol reagent solution at a titer of $2 \times 10^6$ pfu/ml.

MERS viral RNA was isolated according to a standard protocol (Life Technologies). First, chloroform (0.2 ml/ml) was added to the virus homogenate in TRizol. The tube was shaken (15 s) and incubated (2–3 min, room temperature). The sample was centrifuged at 12,000 g for 15 min at 4 °C, aqueous phase was collected, and glycogen was added (5 mg/ml). RNA was then precipitated by adding an equal volume of isopropanol at room temperature for 10 min. The RNA was pelleted by centrifugation at 10,000 g for 10 min at 4 °C, the supernatant was removed, and the pellet was washed twice by 75% ethanol. Finally, the pellet was dissolved in the nuclease-free water (Life Technologies), aliquoted, and kept at –80 °C.

Virus-specific asymmetric amplicons were obtained in two steps. First, mono- or multiplexed nested SAMRS–AEGIS were run in parallel with a standard–AEGIS one-step RT–PCRs (Life Technologies). Next, the extension without or with translabelation was performed (Fig. 2). Final products from both sets of reactions (SAMRS–AEGIS RT–PCR followed by the extension/conversion and standard–AEGIS RT–PCR followed by extension/conversion) produced artificial AEGIS (ACTZ) and standard (AGTC) amplicons.

**RT–PCR**

SuperScript One-Step RT–PCR with Platinum Taq (Life Technologies) was found to be more sensitive and robust than the other enzyme combinations tested. It was able to support the nested PCR amplification with external primers containing the nonstandard P nucleotide, which pairs with the Z nucleotide [9].

Multiplexed nested one-step RT–PCRs with SAMRS–AEGIS or standard–AEGIS primers were executed with RSV, SARS, Infa, or InfB viral RNA simulants (4 ng/ml) or MERS viral RNA. Reactions were carried out in 1 × reaction mix (Life Technologies) with additional 1.5 mM MgSO4 (final volume, 20 μl) according to the Invitrogen protocol for the SuperScript One-Step RT–PCR with Platinum Taq (Life Technologies). The reaction mixture contained 0.2 mM dZTP, 0.025 μM of all sets of forward and reverse hybrid SAMRS–AEGIS or standard AEGIS target-specific primers, 0.25 μM external AEGIS forward and reverse biotinylated primers, and 2.5 U of RT/Platinum Taq enzyme mix. Cycling conditions for subsequent reactions were as follows: 1 cycle of the complementary DNA (cDNA) synthesis and pre-denaturation (53 °C for 30 min and 94 °C for 2 min), 35 cycles of PCR (94 °C for 15 s, 54 °C for 30 s, and 70 °C for 30 s), and final extension at 72 °C (5 min). A “no-target” PCR negative control was included with each assay. MERS virus reactions were executed at higher temperature: 55 °C for 30 min and 94 °C for 2 min and then 35 cycles of PCR (94 °C for 15 s, 56 °C for 30 s, and 70 °C for 30 s). To favor incorporation of biotin-labeled reverse primers to maximize hybridization sensitivity, the second PCR was performed with reverse biotinylated primer only (reverse primer extension reaction, RPER).

**Digestion of excess primers and dNTPs and RPER**

To destroy excess primers and deactivate dNTPs prior to reverse primer extension reaction, ExoSAP-IT enzymes mixture (2 μl;
Affymetrix, Cleveland, OH, USA) was added to aliquots (5 μl) of standard-AEGIS or SAMRS—AEGIS nested PCR. The mixtures were incubated at 37 °C (30 min). The enzymes were inactivated by heating at 80 °C (20 min). The treated PCR products (3 μl) were then added directly to the RPER. Briefly, an RPER (20 μl) was done in 1 × Thermopol Buffer (20 mM Tris–HCl, 10 mM (NH₄)₂SO₄, pH 8.0) to give a final volume of 100 μl.

**Luminex DHA**

Luminex DHA [11] were performed accordingly to the “no-wash” Luminex protocol as discussed previously [9]. Briefly, aliquots (5 μl) of each extension reaction, without or with transliteration reaction, were transferred to 96-well plates (96-well PCR thermo polystyrene plates, Costar Technologies, Coppell, TX, USA). Hybridization buffer (25 μl of 2 × Tm, 0.4 M NaCl, 0.2 M Tris, and 0.16% Triton X-100, pH 8.0) contained microspheres, each carrying approximately 2500 target-specific probes. The microspheres were vortexed and sonicated for 20 s. The total volume was adjusted to 50 μl by adding 20 μl of ddH₂O. ddH₂O (25 μl) was added to each background well (negative control). The temperature (56 °C) to be used in the Luminex hybridization was chosen in a pilot experiment. Hybridization was performed accordingly to the direct hybridization protocol (DHA) provided by Luminex: 95 °C for 5 min, cool to 56 °C at a speed of 0.1 °C/s, and 15 min at 56 °C. The Tm buffer (25 μl of 1 ×) contained streptavidin–R-phycoerythrin (2 μg, PJSR14, PROzyme, Hayward, CA, USA), added to the hybridization mixture, which was then incubated at 56 °C for 5 min. Hybridization reactions were carried out in triplicate, with no-target controls (“background” wells contained sample buffer) run in replicates of 6. Beads were analyzed for internal bead color and R-phycoerythrin reporter fluorescence using a Luminex 200 analyzer (Luminex xMAP Technology, Luminex) and the xPonent Software solutions. The median Fluorescence intensity (MFI) was computed for each bead type in the sample. The instrument’s gate setting was established before the samples were run and was maintained throughout the course of the study.

**Table 3** Hybrid SAMRS—AEGIS primers and AEGIS probes designed for respiratory panel.

| Virus | Primer and probe sequences (5’–3’) | Targeted region |
|-------|-----------------------------------|-----------------|
| Respiratory syncytial virus (RSV) | Forward primer: CATPTCCPCCAPCPAPC GGGCAATATGGGAAACATACAA*C*C*T*G | Pneumovirus matrix protein gene |
| Severe acute respiratory syndrome (SARS) | Forward primer: CAGAAGGCTTCCTACAG*A*A*C*G | Orf1ab polyprotein gene |
| Influenza A (InfA) | Forward primer: CCATGAGGTCTGCTACAA*C*A*C | Segment 7 matrix protein 2 (M2) and matrix protein 1 (M1) genes |
| Influenza B (InfB) | Forward primer: GAGTGGACGTACGACAGTTG*T*A*C*C | Segment 8 nuclear export protein (NEP) and nonstructural protein 1 (NS1) genes |
| Middle East respiratory syndrome (MERS) 1–2 | Forward primer: GTCTACAAAGGCGACAACCTTGGCGTAGTATC*C*A*A*G | ORF1a |
| MERS 2–1 | Forward primer: CTCGCGGTCTCACCTCGCTACCC*A*C/G | Region S |
| MERS 2 | Forward primer: GCTGCTTAATCCGCGACCTCCTACCA*C/A/G | ORF1a |
| MERS 4–1 | Forward primer: CACACCGCTGTTGCTACACCC*C/A/G | ORF1b |
| MERS 6–1 | Forward primer: GAGTGCGTTGCTTGGACAGCTTGGGATC*C/T/G | N and ORF8b |
| MERS UpE | Forward primer: TATCGGTGCTCTTGACCAA*A*T*T*G | S2 glycoprotein |

Note. Probes are 5′ amino modified. AEGIS tags in primers are underlined. P: AEGIS nucleotide (Fig. 1). A*, T*, G*, C*: SAMRS nucleotides.

**Probe coupling to Luminex MicroPlex carboxylated microspheres**

Capture probes modified with an amino-C12 linker at the 5′ end were coupled to Luminex MicroPlex carboxylated microspheres (“beads”) (Luminex, Austin, TX, USA) by a carbodiimide-based procedure according to the manufacturer’s protocol. For each combination of probe and bead set, 2.5 million Luminex beads were resuspended in 0.1 M Mesi buffer (morpholinolium ethansulfonate, 50 μl, pH 4.5, Sigma—Aldrich), with probe (4 μl of 0.1 mM stock to give 0.4 mM final concentration), and treated twice with 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (EDC; 5 μl of a 10-mg/ml solution, Thermo Scientific/Pierce, Rockford, IL, USA; room temperature, 30 min), rinsed in Tween 20 (0.02%aq solution), and then rinsed with a sodium dodecyl sulfate solution (0.1%) and resuspended in Tris–EDTA buffer (pH 8.0) to give a final volume of 100 μl.
Amplicons obtained without transliteration (containing the four standard nucleotides, AGTC) or with transliteration (containing the nucleotides AGT with AEGIS Z), each with sequences specific for their viral originators and biotinylated (see “RT−PCR” and “Digestion of excess primers and dNTPs and RPER” sections above), were hybridized one at a time to a set of all target-specific AEGIS (APTC) or standard (AGTC) probes designed for the panel (Table 3), respectively, each immobilized to a unique microsphere population, analyzed by the Luminex 200 instrument, and expressed as MFI units. The samples were undiluted PCR products. Negative controls, “primers,” were executed with all PCR components and primers. Assays were considered specific and positive if their “true match” MFI were greater than 5 times background and the negative PCR control, and no nonspecific hybridization resulted in MFIs greater than 20% of the true match.

Results

Oligo design and RNA production

For the multiplexed respiratory panel based on the SAMRS − AEGIS−transliteration technology [4,8], five medically important viruses (SARS, RSV, InfA, InfB, and MERS) were targeted (Table 1). Primers and probes for the panel were designed with the FIA/MFirebird in-house StrainTargeter software [9]. One set of primers and a probe were designed for each virus of interest except MERS, where two sets were designed. This overdetermination reflected the Centers for Disease Control and Prevention (CDC) requirement that two specific genomic targets be detected for laboratory confirmation of a MERS viral infection (http://www.cdc.gov/coronavirus/mers/lab/lab-testing.html#molecular). Furthermore, to evaluate the compatibility of two targets from nonrelated genomic regions, several alternative sets of oligos were designed for MERS virus (Tables 2 and 3).

Viral simulant RNAs for InfA, InFB, RSV, and SARS were produced by the in vitro transcription using T7 RNA polymerase and the appropriate ssDNA templates; MERS viral full genomic RNA was isolated from TRIzol reagent solution.

Evaluation of MERS virus by RT−PCR and multiplexed xMAP Luminex DHA platform

The target-specific hybrid standard−AEGIS or SAMRS−AEGIS forward and reverse primer pairs designed for the panel were tested first by monoplexed one-step nested RT−PCR with full genomic MERS RNA followed by extension without or with transliteration as described earlier (“RT−PCR” and “Digestion of excess primers and dNTPs and RPER” sections and Fig. 3A). Each monoplexed RT−PCR produced the expected amplicons, which was visualized by the ethidium bromide staining following electrophoresis (data not shown). Next, the identity of each PCR product was confirmed by the hybridization on Luminex platform. Asymmetric biotinylated amplicons obtained either without transliteration (containing the standard ATGC nucleotides) or with transliteration (containing the standard ATG nucleotides and the AEGIS Z nucleotide) were hybridized one at a time to a set of 11 target−specific standard (AGTC) or AEGIS (APTC) probes (Table 3), each covalently attached to a unique microsphere population and analyzed by the Luminex 200 instrument (Fig. 3A).

The MERS UpE assay generated false positive fluorescent signals in the InfA channels (8-fold over background level). The MERS 2 assay generated signal when presented with the MERS virus but also with InfA (10- and 5-fold and 4-fold over background level). However, the MERS 1−2, 2−1, 4−1, and 6−1 biotinylated amplicons generated fluorescent signals only when the MERS virus was present; no background was seen. Further winnowing the primer/target sets, we observed that the MERS 4−1 primers gave lower signal (6− to 12-fold lower) than MERS 1−2, 2−1, and 6−1 amplicons. Thus, the MERS 4−1 primer/probe set was set aside, with its ORF8b region being covered by the 6−1 primer/probe set (Fig. 3A).

To confirm the compatibility of the primers used to detect MERS with the primers used to detect other viruses, MERS simulant ORF1a (1−2, 2−1) and N/ORF8b (6−1) RNA was presented in an assay that contained the primers/probes/beads for all viruses; the assay mixture capable of full multiplexed detection was then evaluated on the Luminex platform (Fig. 3A) containing all of the beads (Table 3). MERS was detected with the highest fluorescent signals (5000−6000 MFI units) with the 1−2 and 6−1 primer/probe sets, which simultaneously detected two genomic regions of the MERS virus (ORF1a and N/ORF8b). The signals indicating the presence of these MERS genomic sequences were approximately 2− to 3-fold higher when transliteration was included.

In a pilot experiment, the 6-fold multiplexed SAMRS−AEGIS nested RT−PCRs were set up with InfA, InFB, RSV, and SARS viral RNA simulants and complete MERS viral RNA. Amplifications were done in parallel under conditions shown to be most sensitive for MERS (reverse transcription at 55 °C and PCR primers annealing at 55−56 °C). The transliterated AGTZ products were analyzed on the Luminex platform in the presence of beads that could detect all viruses in the panel.

Strong signals indicated, in turn, the presence of each virus without any off-target signal except RSV. When the multiplex was challenged to detect RSV, it correctly created a strong positive signal arising from the RSV−specific Luminex beads but also gave a false signal (50−60%) that might be misinterpreted as indicating the presence of InfA as well. The reason for this was unfavorable conditions for RSV RT−PCR. This cross-reactivity appeared to arise from the fact that optimal conditions to amplify the MERS targets were suboptimal for discriminating between RSV and InfA (Fig. 3C). To resolve this problem, two groups of RT−PCR incubations were done in parallel, each under its optimal conditions. The first group included MERS target sets 1−2 and 6−1, and the second group included InfA, InFB, RSV, and SARS.

Validation of biotinylated PCR amplicons on 6-fold multiplexed xMAP Luminex DHA platform

The second 4-fold multiplexed SAMRS−AEGIS or standard−AEGIS nested RT−PCRs were set up with InfA, InFB, RSV, and SARS viral RNA simulants at optimal RT−PCR conditions (see “Digestion of excess primers and dNTPs and RPER” section in Materials and Methods and previous section above). Amplicons were then visualized on ethidium bromide gel as resolved bands of the expected sizes (113−160 bp) (Figs. 3B and 4A).

SAMRS−AEGIS RT−PCR amplicons validation

The identity of each amplicon produced by multiplexed PCR followed by extension reactions without and with transliteration (Fig. 2) was confirmed by hybridization with the specific probes on a multiplexed Luminex xMAP DHA platform (Fig. 3C). Standard (AGTC) or transliterated (AGTZ) virus-specific biotinylated amplicons were hybridized to a set of six target-specific AEGIS (APTC) or standard (AGTC) probes designed for the panel, two for the MERS targets (sets 1−2 and 6−1) and four for the rest of the panel members (Table 3).

In the presence of target RNA, all assays were positive. Background fluorescence was low, in the range of 20−50 MFI units.
Fig. 3. (A) Evaluation of MERS RT–PCR/Luminex targets. The products of monoplexed (top panel) and 2- or 3-fold multiplexed (bottom panels) MERS viral RT–PCRs and conversion PCRs (with transliteration) were analyzed by Luminex direct hybridization assays (DHAs) with all AGTZ probes generated for the respiratory assays panel. The panels from the right indicate viral targets and Luminex bead identities. (B) A total of 35 cycles of nested multiplexed RT–PCRs performed with target-specific internal SAMRS nucleotide primers flanked by AEGIS tags and external AEGIS primers. Reactions were executed with RNA simulants (5 ng per reaction) and MERS viral full genomic RNA (M1–M3, 10^2–10^4 genomes per reaction). Aliquots of the reaction mixture (4 μl of each 20 μl) were loaded on a 2.5% TBE gel and visualized by the ethidium bromide staining. (C) Luminex DHA performed with amplicons generated by multiplexed nested SAMRS–AEGIS RT–PCRs followed by dC-to-dZ extension with transliteration (conversion) or without transliteration (extension). Samples were undiluted PCR products. Background, negative control, and sample buffer were added to the Luminex mixture. The panel from right indicates viral targets and Luminex bead identities. (C) Luminex profiles of standard (AGTC, extension, red bars) versus transliterated AEGIS (AGTZ, conversion, blue bars) amplicons. The averages of three independent experiments are presented. MFI: median fluorescence intensity (mean ± standard deviation). The viruses were InfA, InfB, RSV, SARS, and MERS. Prim: primers control. (For interpretation of the reference to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4. (A) A total of 35 cycles of nested multiplexed RT-PCRs performed with target-specific internal standard nucleotide primers flanked by AEGIS tags and external AEGIS primers. Reactions were executed with viral RNA simulants (5 ng per reaction) or MERS viral full genomic RNA (10⁴ genomes). Aliquots of the reaction mixture (4 µl of each 20 µl) were loaded on a 2.5% TBE gel and visualized by the ethidium bromide staining. (B) Luminex DHA performed with amplicons generated by multiplexed RT-PCRs and by dC-to-dZ transliteration (conversion) or extension without transliteration (extension) reactions. Luminex samples were undiluted PCR products. Background, negative control, and sample buffer were added to the Luminex mixture. The panel from the right indicates viral targets and Luminex bead identities. The panel on the bottom displays Luminex profiles summary for standard (AGTC, extension, red bars) versus AEGIS (AGTZ, conversion, blue bars) amplicons. (C) AGTZ amplicons Luminex profiles: Standard-AEGIS versus SAMRS-AEGIS RT-PCR amplicons. The average of the three independent experiments is presented. MFI: median fluorescence intensity (mean ± standard deviation). The viruses were InfA, InfB, RSV, SARS, and MERS (10⁴ pfu). Prim: primers control. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
(1–3%), for all assays. Strong specific fluorescent signals were generated by all amplicons. However, transliterated amplicons gave stronger signals (5000–9000 MFI units) than untransliterated amplicons (1500–4000 MFI units) (Fig. 3C). This corresponds in this respiratory disease panel to the results that we observed in a panel that targeted mosquito-borne arboviruses [9] and was attributed to the stronger and more uniform binding that dZ:dP displays.

**Value of SAMRSs in RT–PCR amplifications**

The impact of SAMRS components in hybrid primers on assay performance was evaluated by comparing readouts with those obtained from hybrid primers that had standard nucleotides (Fig. 4C). For all targets, stronger signals were obtained with primers containing SAMRSs.

**LOD of MERS by this panel**

The limit of detection (LOD) was estimated with full MERS RNA (Fig. 5). In the sample of complete MERS virus (Reed Johnson, personal communication), viral titer was approximately 10⁶ pfu/ml, corresponding to approximately 10⁸ virions/ml. Serial 10-fold dilutions of MERS RNA were tested using the multiplexed Luminex assay (10⁵, 10⁴, 10³, 10², 10, and 1 pfu/ml), both without and with transliteration with SAMRS–AEGIS primers. With transliteration, 10 virions per 20 μl of sample could be detected (Fig. 5C), with stronger signals from the MERS ORF1a target than the N/ORF8b target. Signals from transliteration were 1.5- to 3-fold higher than those without transliteration (Fig. 5C).

**Discussion**

MERS, SARS, and other respiratory viruses are highly contagious, have many clinical manifestations, and are associated with considerable morbidity and mortality. Thus, they create an economically significant public health threat [12–18], as shown by recent MERS outbreaks in Korea. Therefore, early diagnosis is needed to arrange for quarantines, manage patient care, and help public health officials track disease outbreaks [19,20] (see also http://www.cdc.gov/flu/about/disease/us_flu-related_deaths.htm; http://www.cdc.gov/sars; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6403a4.htm).

Unfortunately, infections caused by these viruses are difficult to detect, especially if the virus is “exotic” to a locale. Thus, although MERS might easily be considered as a cause of respiratory distress for a patient admitted to a hospital in Mecca, Saudi Arabia (and the local physicians might have seen multiple cases of it previously), it is not for a patient admitted to an emergency room in, for example, Orlando, Florida (USA) or Seoul, Korea. Physicians examining patients in the latter locales have no reason to have had experience with viruses outside of their endemic regions. Thus, it is not surprising that a MERS-infected patient admitted to an emergency room in Orlando in 2014 waited for hours before diagnosis.

Time, of course, is critical if quarantine is to be effective. Classical tests based on the detection of patient antibodies or viral culture are too slow, the latter intrinsically and the former due to the lag between the time when a patient is infected and antibodies emerge. For example, some rapid influenza diagnostic tests (RIDTs) generate false negatives in a majority of patients [21]. Viral culture requires up to 21 days [22]. Antibody-based assays that target the virus itself are faster but require substantial viral load.

**Fig. 5.** Limit of MERS virus detection (LOD) by the multiplexed assay. RT–PCRs were executed with 10-fold MERS viral RNA dilutions (10⁵–1 pfu/ml). Assays were executed with AGTZ amplicons generated by 2-fold multiplexed SAMRS–AEGIS nested RT–PCRs and dC-to-dZ conversion reactions (A, C) or with AGTC amplicons generated by 2-fold multiplexed nested standard RT–PCRs and extension reactions (B, C). MFI: median fluorescence intensity. (A, B) The panel from the right indicates target and bead identities. (C) Summary of MERS virus LOD by respiratory multiplexed Luminex platform: Luminex profiles of ATGZ (from transliteration) versus ATGC amplicons (panel from the left: MERS 1–2 target; panel from the right: MERS 6–1 target). Viral loads per PCR: 10⁴ to 0.1 physical viral genomes.
Molecular approaches that detect viral nucleic acids (NAs) are faster. Accordingly, monoplexed assays based on real-time PCR or reverse transcription PCR [23–28] are now the “gold standard” for NA detection in clinical laboratories [29]. Several of these targeting respiratory viruses (some with downstream detection by Luminex LiquiChip platforms) have FDA clearance and are commercially available, including CepheidXpert Flu Assay (Cepheid, Sunnyvale, CA, USA), XTAG Viral Respiratory Panel (Luminex), Prodesse ProFlu (Gen-Probe, San Diego, CA, USA), Film Array (Idaho Technology, Salt Lake City, UT, USA), Liat Influenza (Iquum, Marlborough, MA, USA), ResPlex II Multiplex Assay for Respiratory Pathogens (Qiagen), MultiCode-PLx Respiratory Virus Panel (EraGen Biosciences, Madison, WI, USA), and NGEN RVA ASR (Nanogen, San Diego, CA, USA).

A list of FDA-approved diagnostics kits targeting respiratory viruses by amplification technology is given in Table B1 of the supplementary material. Compared with classical techniques, these have a rapid turnaround time and are more accurate and sensitive (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm#microbial).

PCR assays are, however, expensive in terms of both operator expertise and instrument demands. Furthermore, in a monoplexed format, the diagnostician must “guess correctly” which assay to run to detect one of the diverse viral pathogens, he or she will not run the correct monoplexed assay.

In principle, a multiplexed assay that targets all possible causes of respiratory distress could mitigate the cost and avoid the need for guesswork. A search for the complete spectrum of common and exotic viral infections could be done routinely in a hospital admissions setting by individuals who need not have clinical experience with each and every virus. The ability of an assay to detect an exotic virus might even be “masked” [20]. This would facilitate cost-effective diagnosis by simultaneous detection of several viral pathogens in a single billable procedure, with “unmasking” done only in the case of an emergency.

Unfortunately, simply adding more and more primer pairs to increase the multiplexing of an amplification routinely gives noise, false positive signals, or false negative signals. These are attributed to off-target interactions that are invited in an assay that contains many different DNA molecules at high concentrations. These can compete for and deplete limiting reagents in a PCR [30]. Moreover, the complexity of the combination of reagents often results in a loss of sensitivity for each of the individual targets compared with monoplexed reactions executed in parallel.

Here we showed that the performance of multiplexed RNA-targeted assays can be improved by incorporating synthetic (SAMRS and/or AEGIS) nucleotides in PCR primers and Luminex probes [8,9]. First, self-avoiding molecular recognition systems diminish primer—primer interactions and their resulting artifacts. Second, artificially expanded genetic information systems allow external primers in a nested PCR format to bind nowhere to any natural DNA, conserving these resources for the desired amplification. Last, translocation to give AEGIS-containing amplicons from fully standard amplicons without loss of sequence information allows amplicons to be efficiently and uniformly captured. Of course, as a cautionary note, the assays presented here have yet to be tested in the field with actual samples, where their sensitivity and specificity may differ.

With these innovations, discrimination of all viruses in the panel was possible using Luminex xMAP detection, where individually addressable, color-coded beads are used to capture specific target amplicons. Here the low noise and cleanliness of AEGISs and SAMRSs were manifest. Furthermore, Luminex targets generated by translocation gave higher and more uniform mean fluorescence intensities than standard amplicons. Moreover, two primer sets were especially effective in detecting MERS within an assay that could detect SARS and three more common viruses. Therefore, these results parallel an analogous assay panel that exploited these innovations to detect 22 mosquito-borne arboviruses [9].

We expect that most patients who present with respiratory symptoms in a U.S. emergency room will be suffering from a strain of influenza, RSV, or a less severe pathogen. Very few will have MERS or SARS. However, current trends suggest that the future will see more exotic diseases in more remote environments. Accordingly, we expect these kinds of assays, and the innovations that support them, to become more and more useful and then necessary. Furthermore, nothing constrains the application of these innovations to SARS or MERS; RNA is RNA, regardless of its source, and we can expect the adaptability of the AEGIS—SAMRS—transliteration combination to allow the addition of still more exotic targets to the panel. Researchers are also invited to contact the authors to obtain expanded or alternative primer sets; custom-designed primer sets are also available commercially from Firebird Biomolecular Sciences (http://www.firebirdbio.com).

Appendix A. Supplementary material

Supplementary material for this article is available in the online version at http://dx.doi.org/10.1016/j.jab.2015.08.015.

References

[1] C. Switzer, S.E. Moroney, S.A. Benner, Enzymatic incorporation of a new base pair into DNA and RNA, J. Am. Chem. Soc. 111 (1989) 8322–8323.
[2] T. Elbeik, N. Markowitz, P. Nassos, U. Kumar, S. Beringer, B. Haller, et al., Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow, J. Clin. Microbiol. 42 (2004) 3120–3127.
[3] T. Elbeik, J. Surtihadi, M. Destree, J. Gerlin, M. Holodniy, S.A. Jortani, et al., Multicenter evaluation of the performance characteristics of the Bayer VERSANT HEV RNA 3.0 assay (bDNA), J. Clin. Microbiol. 42 (2004) 563–569.
[4] Z. Yang, F. Chen, S.G. Chamberlin, S.A. Benner, Expanded genetic alphabets in the polymerase chain reaction, Angew. Chem. Int. Ed. 49 (2010) 177–180.
[5] S.C. Johnson, D.J. Marshall, G. Harms, C.M. Miller, C.B. Sherrill, E.L. Beaty, et al., Multiplexed genetic analysis using an expanded genetic alphabet, Clin. Chem. 50 (2004) 2019–2027.
[6] F.S. Nolte, D.J. Marshall, C. Rasberry, S. Scheviebelgen, G.G. Banks, G.A. Storch, et al., MultiCode-PLx system for multiplexed detection of seventeen respiratory viruses, J. Clin. Microbiol. 45 (2007) 2779–2786.
[7] S.A. Benner, H.J. Kim, K.B. Merritt, Z. Yang, C. McLendon, S. Hoshika, D. Hutter, Next-generation DNA in pathogen detection, surveillance, and CLIA-waivable diagnostics, Proc. SPIE 9490, Adv. Glob. Health through Sens. Technol. (2015) 94900X, http://dx.doi.org/10.1117/12.2183481.
[8] Z. Yang, M. Durante, L.G. Glushakova, N. Sharma, N.A. Leal, K.M. Bradley, et al., Conversion strategy using an expanded genetic alphabet to assay nucleic acids, Anal. Chem. 85 (2013) 4705–4712.
[9] L.G. Glushakova, A. Bradley, K.M. Bradley, B.W. Alto, S. Hoshika, D. Hutter, et al., High-throughput multiplexed xMAP Luminex array panel for detection of twenty two medically important mosquito-borne arboviruses based on innovations in synthetic biology, J. Virol. Methods 214 (2015) 60–74.
[10] H. Geng, W. Tan, A novel human coronavirus: Middle East respiratory syndrome human coronavirus, Sci. China Life Sci. 56 (2013) 683–687.
[11] S.A. Dunbar, Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection, Clin. Chim. Acta 363 (2006) 71–82.
[12] S.E. Ellis, C.S. Coffey, E.F. Mitchel Jr., R.S. Dittus, M.R. Griffin, Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population, J. Am. Geriatr. Soc. 51 (2003) 761–767.

[13] W.W. Thompson, D.K. Shay, E. Weintraub, L. Brammer, N. Cox, L.J. Anderson, et al., Mortality associated with influenza and respiratory syncytial virus in the United States, JAMA 289 (2003) 179–186.

[14] A.G. Jansen, E.A. Sanders, A.W. Hoes, A.M. van Loon, E. Hak, Influenza- and respiratory syncytial virus-associated morbidity and hospitalisations, Eur. Resp. J. 30 (2007) 1155–1166.

[15] A.S. Karstaedt, M. Hopley, M. Wong, H.H. Crewe-Brown, A. Tasset-Tisseau, Influenza- and respiratory syncytial virus-associated adult mortality in Soweto, South Afr. Med. J. 99 (2009) 750–754.

[16] T.C. Chan, C.K. Hsiao, C.C. Lee, P.H. Chiang, C.L. Kao, C.M. Liu, et al., The impact of matching vaccine strains and post-SARS public health efforts on reducing influenza-associated mortality among the elderly, PLoS One 5 (2010) e11317.

[17] A. Bermingham, M.A. Chand, C.S. Brown, E. Aarons, C. Tong, C. Langrish, et al., Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, Euro. Surveill. 17 (40) (2012) 20290.

[18] S. Tempia, S. Walaza, C. Viboud, A.L. Cohen, S.A. Madhi, M. Venter, et al., Mortality associated with seasonal and pandemic influenza and respiratory syncytial virus among children < 5 years of age in a high HIV prevalence setting: South Africa, 1998–2009, Clin. Infect. Dis. 58 (2014) 1241–1245.

[19] S.C. Kehl, S. Kumar, Utilization of nucleic acid amplification assays for the detection of respiratory viruses, Clin. Lab. Med. 29 (2009) 661–671.

[20] J.B. Mahony, A. Petrich, M. Smieja, Molecular diagnosis of respiratory virus infections, Crit. Rev. Clin. Lab. Sci. 48 (2011) 217–245.

[21] C.C. Ginocchio, Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens, Clin. Infect. Dis. 52 (Suppl. 4) (2011) S312–S325.